CDKN2A and B-cell chronic lymphocytic leukemia: As shown by Märklin et al. (26), NFAT loss leads to an RS phenotype in the CLL mouse model with loss of the cell cycle inhibitors CDKN2A-p14 and TP53 and the activation of AKT.